LIVER

Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance

G Donati¹, B Stagni¹, F Piscaglia¹, N Venturoli², A M Morselli-Labate¹, L Rasciti¹, L Bolondi¹

¹ Division of Internal Medicine, Department of Internal Medicine and Gastroenterology, University of Bologna, Azienda S Orsola-Malpighi, Bologna, Italy
² Regional Center for Transplantation, Azienda S Orsola-Malpighi, Bologna, Italy

Correspondence to:
Correspondence to:
Dr F Piscaglia
Department of Internal Medicine and Gastroenterology, University of Bologna, via Albertoni 15, 40138, Bologna, Italy; Piscagl{at}med.unibo.it

Background: The conditions associated with fatty liver disease presenting with normal liver enzymes and the mechanism involved in its development remain to be fully elucidated.

Aims: The aim of the present study was to test the hypothesis that fatty liver with normal liver enzymes occurs more frequently in arterial hypertensive patients and to establish whether this condition is associated with insulin resistance.

Patients: A total of 55 non-obese, non-diabetic, non-heavy alcohol drinking patients with arterial hypertensive and normal liver enzymes and 55 sex and age matched healthy subjects were enrolled into the study.

Methods: Plasma metabolic parameters, body mass index, and the presence of fatty liver were investigated. Insulin resistance was estimated from plasma insulin and glucose as the homeostasis model assessment index. Stepwise logistic regression and multivariate regression analysis were used on the combined sample to identify variables independently associated with fatty liver and insulin resistance.

Results: Hypertensive patients had a significantly higher prevalence of fatty liver (30.9% v 12.7%; p<0.041), higher insulin resistance (mean 2.27 (SD 1.81) v 1.56 (0.70); p = 0.022), and slightly higher body mass index (24.9 (3.0) v 24.0 (2.2); p = 0.043) than controls. Multivariate logistic regression identified insulin resistance (odds ratio 1.66 (95% confidence interval (CI) 1.03–2.52)) and body mass index (OR 1.22 (95% CI 1.00–1.49)) as factors independently associated with fatty liver. Multivariate regression analysis showed insulin resistance to be predicted by alanine transaminase (p = 0.002), presence of arterial hypertension (p = 0.029), and body mass index (p = 0.048).

Conclusion: The higher prevalence of non-alcoholic fatty liver in non-obese hypertensive patients with normal liver enzymes appears to be related to increases in insulin resistance and body weight.

Abbreviations: GT, gamma glutamyl transpeptidase; US, ultrasonography; HDL, high density lipoprotein; ALT, alanine transaminase; AST, aspartate transaminase; HOMA, homeostasis model assessment index

Keywords: fatty liver; body mass index; insulin resistance; arterial hypertension

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Fatty liver, hypertension, and the metabolic syndrome

A M Diehl
Gut 2004 53: 923-924. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Chang, Y, Ryu, S, Sung, E, Woo, H-Y, Cho, S-I, Yoo, S-H, Ahn, H-Y, Choi, N-K (2009). Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut 58: 1419-1425 [Abstract] [Full Text]  
• Wei, Y., Clark, S. E., Thyfault, J. P., Uptergrove, G. M.E., Li, W., Whaley-Connell, A. T., Ferrario, C. M., Sowers, J. R., Ibdah, J. A. (2009). Oxidative Stress-Mediated Mitochondrial Dysfunction Contributes to Angiotensin II-Induced Nonalcoholic Fatty Liver Disease in Transgenic Ren2 Rats. Am. J. Pathol. 174: 1329-1337 [Abstract] [Full Text]  
• Clemenz, M., Frost, N., Schupp, M., Caron, S., Foryst-Ludwig, A., Bohm, C., Hartge, M., Gust, R., Staels, B., Unger, T., Kintscher, U. (2008). Liver-Specific Peroxisome Proliferator-Activated Receptor {alpha} Target Gene Regulation by the Angiotensin Type 1 Receptor Blocker Telmisartan. Diabetes 57: 1405-1413 [Abstract] [Full Text]  
• Pravenec, M., Kazdova, L., Landa, V., Zidek, V., Mlejnek, P., Simakova, M., Jansa, P., Forejt, J., Kren, V., Krenova, D., Qi, N., Wang, J.-M., Chan, D., Aitman, T. J., Kurtz, T. W. (2008). Identification of Mutated Srebf1 as a QTL Influencing Risk for Hepatic Steatosis in the Spontaneously Hypertensive Rat. Hypertension 51: 148-153 [Abstract] [Full Text]  
• Shibata, M., Kihara, Y., Taguchi, M., Tashiro, M., Otsuki, M. (2007). Nonalcoholic Fatty Liver Disease Is a Risk Factor for Type 2 Diabetes in Middle-Aged Japanese Men. Diabetes Care 30: 2940-2944 [Abstract] [Full Text]  
• Zivkovic, A. M, German, J B., Sanyal, A. J (2007). Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am. J. Clin. Nutr. 86: 285-300 [Abstract] [Full Text]  
• Mcavoy, N. C, Ferguson, J. W, Campbell, I. W, Hayes, P. C (2006). Review: Non-alcoholic fatty liver disease: natural history, pathogenesis and treatment. British Journal of Diabetes & Vascular Disease 6: 251-260 [Abstract]  
• Sugimoto, K., Qi, N. R., Kazdova, L., Pravenec, M., Ogihara, T., Kurtz, T. W. (2006). Telmisartan But Not Valsartan Increases Caloric Expenditure and Protects Against Weight Gain and Hepatic Steatosis. Hypertension 47: 1003-1009 [Abstract] [Full Text]  
• Hamaguchi, M., Kojima, T., Takeda, N., Nakagawa, T., Taniguchi, H., Fujii, K., Omatsu, T., Nakajima, T., Sarui, H., Shimazaki, M., Kato, T., Okuda, J., Ida, K. (2005). The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease. ANN INTERN MED 143: 722-728 [Abstract] [Full Text]  
• Valtuena, S., Numeroso, F., Ardigo, D., Pedrazzoni, M., Franzini, L., Piatti, P. M., Monti, L., Zavaroni, I. (2005). Relationship between leptin, insulin, body composition and liver steatosis in non-diabetic moderate drinkers with normal transaminase levels. Eur J Endocrinol 153: 283-290 [Abstract] [Full Text]  
• Ryan, M. C., Wilson, A. M., Slavin, J., Best, J. D., Jenkins, A. J., Desmond, P. V. (2005). Associations Between Liver Histology and Severity of the Metabolic Syndrome in Subjects With Nonalcoholic Fatty Liver Disease. Diabetes Care 28: 1222-1224 [Full Text]  
• Qi, N. R., Wang, J., Zidek, V., Landa, V., Mlejnek, P., Kazdova, L., Pravenec, M., Kurtz, T. W. (2005). A New Transgenic Rat Model of Hepatic Steatosis and the Metabolic Syndrome. Hypertension 45: 1004-1011 [Abstract] [Full Text]  
• Kerner, A., Avizohar, O., Sella, R., Bartha, P., Zinder, O., Markiewicz, W., Levy, Y., Brook, G. J., Aronson, D. (2005). Association Between Elevated Liver Enzymes and C-Reactive Protein: Possible Hepatic Contribution to Systemic Inflammation in the Metabolic Syndrome. Arterioscler. Thromb. Vasc. Bio. 25: 193-197 [Abstract] [Full Text]  
• Diehl, A M (2004). Fatty liver, hypertension, and the metabolic syndrome. Gut 53: 923-924 [Full Text]